Throughout the last three months, 18 analysts have evaluated Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 12 | 5 | 1 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 7 | 2 | 1 | 0 | 0 |
2M Ago | 1 | 1 | 0 | 0 | 0 |
3M Ago | 3 | 2 | 0 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $91.94, a high estimate of $120.00, and a low estimate of $77.00. Marking an increase of 11.44%, the current average surpasses the previous average price target of $82.50.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis...
Login or create a forever free account to read this news
Sign up/Log in